Organ and Tissue Transplantation and Alternatives
January 1, 2011259 Pages
- SKU: WA6122367
REASONS FOR DOING THE STUDY
The objective of this study is to provide an in-depth analysis and forecast of the solid organ and tissue transplantation markets. The focus is on products and procedures used or under development for organ and tissue transplantations, including techniques, therapies, drugs, and diagnostics. Additionally, a market analysis of alternative transplantations with devices such as ventricular assist devices (VAD), total artificial hearts (TAH), and orthopedic replacement and reconstruction devices will be explored.
STUDY GOALS AND OBJECTIVES
Organ transplantation is a dynamic field, with continuing progress in the development of artificial organs and transplantation methods that reduce rejection and infection. There are increased pressures to ensure transplantation methods are as efficient and effective as possible because the need for organ donors far outstrips the availability of organs and tissues
In theory, transplantation is the last therapeutic option available to people in the final stage of an organ or tissue failure. In reality, the supply of organs or tissues is so limited that for the vast majority of people, transplantation is not an option. Despite the lack of organs, the transplantation business continues to innovate through better harvesting and procurement techniques, vastly improved immunosuppression regimens, advanced tissue matching, and effective anti-infective regimens, all of which have helped build the organ and tissue transplantation business to a maturing stage.
This report will focus on procurement and preservation, solid organ transplantation, tissue transplantation, immunosuppressives and other pharmaceuticals, post-transplantation concerns, and alternatives to transplantation. Although the organ transplantation business faces tough challenges, it also offers exciting fields of research and tremendous opportunities to meet growing market demand.
With transplant recipients living much longer, there is a growing need for post-transplant immunosuppression and monitoring. This aspect of the transplantation process will be covered, describing post-transplant drug regimens and patient and graft survival rates.
This report is a valuable tool for anyone assessing the organ and tissue transplantation market and attempting to devise a strategy to successfully compete in this market. This report provides a thorough background on the structure of the organ and tissue transplantation market and the chief challenges and opportunities it faces. It offers the information needed to understand the current market and to address the emerging one.
This is an invaluable tool for business planners, acquisitions specialists, licensing strategists, product managers, market research analysts, investing consultants, and others interested in the tissue and transplantation market, its products, its participants, and its future.
SCOPE OF REPORT
This report offers forecasts, by product segment, from 2010 through 2015, including supporting analyses for projections. Product segments covered consist of solid organ (e.g., kidneys, liver, heart-lung, pancreas, intestines) and the tissue transplantation (e.g., bone, skin, cornea, heart valves) markets, along with the pharmaceuticals that accompany each market.
Also included are experimental xenografts and artificial organs; tissue transplants; and cell transplants (e.g., bone marrow, cord blood, peripheral blood, islet cell). The report touches on the use of fetal cells, stem cells, and altered cancer cells.
The arrangement of this report offers an overview of the key elements in the transplantation process: tissue typing, procurement and preservation, immunosuppressants for solid organ and tissue transplants, and postoperative monitoring. International markets are discussed, and information is provided on industry structure and the regulatory environment.
Within each section are discussions of commercialization opportunities for each segment of the market. New or emerging devices, techniques, and pharmaceuticals are highlighted.
Profiles of more than 50 leading companies involved with solid organ transplantation, tissue transplantation, and alternative technologies are included. The report provides information on company placement within the market and strategic analyses of the companies’ available and emerging products.
An appendix featuring various terms and processes used in transplantation is provided at the end of the report.
This report cites autologous products only in relation to their impact on the market for allografts. It does not include blood products, with the exception of peripheral and umbilical cord blood as a source of stem cells.
METHODOLOGIES AND INFORMATION SOURCES
Information for this report was derived from a variety of primary and secondary research sources, including industry analysts, annual reports and Securities and Exchange Commission (SEC) reports, the United Network for Organ Sharing (UNOS), the Organ Procurement and Transplantation Network (OPTN), the Scientific Registry of Transplant Recipients (SRTR), the Center for Medicare and Medicaid Services (CMS), the National Institutes of Health (NIH), the Centers for Disease Control (CDC), other government agencies, and journal articles. Secondary sources include literature searches; product literature; and press releases.
When precise information was not available, a consensus was made using reasonable assumptions and estimates based on historical data.
More United States Blood Supply, Tissue Banking, Transplantation reports
The 2013-2018 Outlook for Tissue Transplantation Products and Services in the United States by Icon Group International, Inc.
The 2013-2018 Outlook for Tissue Transplantation Products and Services in the United StatesThis econometric study covers the latent demand outlook for tissue transplantation products and ...
The 2013-2018 Outlook for Organ Preservation Solutions in the United States by Icon Group International, Inc.
The 2013-2018 Outlook for Organ Preservation Solutions in the United StatesThis econometric study covers the latent demand outlook for organ preservation solutions across the states ...
The 2013-2018 Outlook for Artificial Organs in the United States by Icon Group International, Inc.
The 2013-2018 Outlook for Artificial Organs in the United StatesThis econometric study covers the latent demand outlook for artificial organs across the states and cities ...
See all reports like this >>
The 2013-2018 Outlook for Artificial Kidneys in the United States by Icon Group International, Inc.
The 2013-2018 Outlook for Artificial Kidneys in the United StatesThis econometric study covers the latent demand outlook for artificial kidneys across the states and cities ...
More United States reports
The 2013-2018 Outlook for Collagen and (hyaluronic Acid) HA-Based Biomaterials in the United States by Icon Group International, Inc.
The 2013-2018 Outlook for Collagen and (hyaluronic Acid) HA-Based Biomaterials in the United StatesThis econometric study covers the latent demand outlook for collagen and (hyaluronic ...
See all reports like this >>
The 2013-2018 Outlook for Relish in the United States by Icon Group International, Inc.
This econometric study covers the latent demand outlook for relish across the states and cities of the United States. Latent demand (in millions of U.S. ...
Blood Supply, Tissue Banking, Transplantation Reports
Share this report
Join Alert Me now!
Receive bi-weekly email alerts on new market research Sign up today!